Our top pick for
NantKwest, Inc is a biotechnology business based in the US. NantKwest shares (NK) are listed on the NASDAQ and all prices are listed in US Dollars. NantKwest employs 160 staff and has a trailing 12-month revenue of around USD$99,000.
Since the stock market crash in March caused by coronavirus, NantKwest's share price has had significant positive movement.
Its last market close was USD$8.38, which is 31.38% up on its pre-crash value of USD$5.75 and 222.31% up on the lowest point reached during the March crash when the shares fell as low as USD$2.6.
If you had bought USD$1,000 worth of NantKwest shares at the start of February 2020, those shares would have been worth USD$421.53 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,252.64.
|Latest market close||USD$8.38|
|52-week range||USD$1.35 - USD$15.7|
|50-day moving average||USD$8.2399|
|200-day moving average||USD$8.7656|
|Wall St. target price||USD$13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.893|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||N/A|
|1 month (2020-10-30)||11.58%|
|3 months (2020-08-28)||N/A|
|6 months (2020-05-28)||N/A|
|1 year (2019-11-27)||N/A|
|2 years (2018-11-27)||N/A|
|3 years (2017-11-27)||N/A|
|5 years (2015-11-27)||N/A|
Valuing NantKwest stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NantKwest's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NantKwest's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.56. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NantKwest's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||USD$43,000|
|Return on assets TTM||-28.19%|
|Return on equity TTM||-53.34%|
|Market capitalisation||USD$947.5 million|
TTM: trailing 12 months
There are currently 6.8 million NantKwest shares held short by investors – that's known as NantKwest's "short interest". This figure is 6.2% up from 6.4 million last month.
There are a few different ways that this level of interest in shorting NantKwest shares can be evaluated.
NantKwest's "short interest ratio" (SIR) is the quantity of NantKwest shares currently shorted divided by the average quantity of NantKwest shares traded daily (recently around 954684.95077356). NantKwest's SIR currently stands at 7.11. In other words for every 100,000 NantKwest shares traded daily on the market, roughly 7110 shares are currently held short.
However NantKwest's short interest can also be evaluated against the total number of NantKwest shares, or, against the total number of tradable NantKwest shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NantKwest's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 NantKwest shares in existence, roughly 60 shares are currently held short) or 0.1808% of the tradable shares (for every 100,000 tradable NantKwest shares, roughly 181 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NantKwest.
Find out more about how you can short NantKwest stock.
We're not expecting NantKwest to pay a dividend over the next 12 months.
NantKwest's shares were split on a 8:1 basis on 17 August 2012. So if you had owned 1 share the day before before the split, the next day you'd have owned 8 shares. This wouldn't directly have changed the overall worth of your NantKwest shares – just the quantity. However, indirectly, the new 87.5% lower share price could have impacted the market appetite for NantKwest shares which in turn could have impacted NantKwest's share price.
Over the last 12 months, NantKwest's shares have ranged in value from as little as $1.35 up to $15.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NantKwest's is 2.5231. This would suggest that NantKwest's shares are significantly more volatile than the average for this exchange and represent a higher risk.
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Everything we know about the Sabic IPO, plus information on how to buy in.
Everything we know about the Compass IPO, plus information on how to buy in.
Everything we know about the Marqeta IPO, plus information on how to buy in.
Everything we know about the Pharming Group N.V. IPO, plus information on how to buy in.
Everything we know about the Metromile IPO, plus information on how to buy in.
Everything we know about the CN Energy Group IPO, plus information on how to buy in.
Everything we know about the Huadi International Group IPO, plus information on how to buy in.
Everything we know about the 908 Devices IPO, plus information on how to buy in.
Steps to owning and managing LEGH, with 24-hour and historical pricing before you buy.
Steps to owning and managing LAKE, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.